Boehringer Ingelheim Ltd. and IBM Canada plan to explore the use of blockchain technology in clinical trials. This collaboration marks the first time that blockchain technology will be explored in a clinical trial setting in Canada. 

Based on the findings of regulatory authorities, processes to ensure the quality of clinical trials are frequently inadequate, and clinical trial records are often erroneous or incomplete, which may put patient safety and interpretability of trials at risk.

The alliance aims to improve the quality of clinical trial processes and record keeping by testing whether blockchain technology in clinical trials provides a decentralized framework that enables data integrity, provenance, transparency, and patient empowerment as well as automation of processes, ultimately improving trial quality and patient safety at reduced cost. 

“Our guiding philosophy is to bring value to patients and the healthcare system through innovation,” said Dr. Uli Brödl, vice president, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. “The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment. Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment.”

“IBM is excited to collaborate with Boehringer Ingelheim to explore how blockchain technology could help improve the quality of clinical trials,” said Claude Guay, general manager, IBM Services, IBM Canada. “We’ve been using blockchain in other industries, and we are now investigating how we can use this technology to give Canadian patients the same level of security and trust when it comes to their personal health information.”